Your browser doesn't support javascript.
loading
NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology.
Mock, Andreas; Teleanu, Maria-Veronica; Kreutzfeldt, Simon; Heilig, Christoph E; Hüllein, Jennifer; Möhrmann, Lino; Jahn, Arne; Hanf, Dorothea; Kerle, Irina A; Singh, Hans Martin; Hutter, Barbara; Uhrig, Sebastian; Fröhlich, Martina; Neumann, Olaf; Hartig, Andreas; Brückmann, Sascha; Hirsch, Steffen; Grund, Kerstin; Dikow, Nicola; Lipka, Daniel B; Renner, Marcus; Bhatti, Irfan Ahmed; Apostolidis, Leonidas; Schlenk, Richard F; Schaaf, Christian P; Stenzinger, Albrecht; Schröck, Evelin; Hübschmann, Daniel; Heining, Christoph; Horak, Peter; Glimm, Hanno; Fröhling, Stefan.
Afiliación
  • Mock A; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Teleanu MV; Institute of Pathology, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
  • Kreutzfeldt S; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Heilig CE; Department of Hematology, Oncology and Rheumatology, Heidelberg Unversity Hospital, Heidelberg, Germany.
  • Hüllein J; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Möhrmann L; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Jahn A; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany.
  • Hanf D; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Kerle IA; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Singh HM; Department of Translational Medical Oncology, National Center for Tumor Diseases/University Cancer Center (NCT/UCC) Dresden, Dresden, Germany.
  • Hutter B; DKFZ, Heidelberg, Germany.
  • Uhrig S; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Fröhlich M; Institute for Clinical Genetics, University Hospital Carl Gustav Carus, Technische Universität Dresden and Hereditary Cancer Syndrome Center Dresden, Dresden, Germany.
  • Neumann O; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Hartig A; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Brückmann S; Department of Translational Medical Oncology, National Center for Tumor Diseases/University Cancer Center (NCT/UCC) Dresden, Dresden, Germany.
  • Hirsch S; DKFZ, Heidelberg, Germany.
  • Grund K; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Dikow N; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Lipka DB; Department of Translational Medical Oncology, National Center for Tumor Diseases/University Cancer Center (NCT/UCC) Dresden, Dresden, Germany.
  • Renner M; DKFZ, Heidelberg, Germany.
  • Bhatti IA; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Apostolidis L; Department of Medical Oncology, NCT Heidelberg and Heidelberg University Hospital, Heidelberg, Germany.
  • Schlenk RF; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany.
  • Schaaf CP; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany.
  • Stenzinger A; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany.
  • Schröck E; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Hübschmann D; Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Heining C; Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Horak P; Institute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany.
  • Glimm H; Institute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany.
  • Fröhling S; Institute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany.
NPJ Precis Oncol ; 7(1): 109, 2023 Oct 26.
Article en En | MEDLINE | ID: mdl-37884744
ABSTRACT
Analysis of selected cancer genes has become an important tool in precision oncology but cannot fully capture the molecular features and, most importantly, vulnerabilities of individual tumors. Observational and interventional studies have shown that decision-making based on comprehensive molecular characterization adds significant clinical value. However, the complexity and heterogeneity of the resulting data are major challenges for disciplines involved in interpretation and recommendations for individualized care, and limited information exists on how to approach multilayered tumor profiles in clinical routine. We report our experience with the practical use of data from whole-genome or exome and RNA sequencing and DNA methylation profiling within the MASTER (Molecularly Aided Stratification for Tumor Eradication Research) program of the National Center for Tumor Diseases (NCT) Heidelberg and Dresden and the German Cancer Research Center (DKFZ). We cover all relevant steps of an end-to-end precision oncology workflow, from sample collection, molecular analysis, and variant prioritization to assigning treatment recommendations and discussion in the molecular tumor board. To provide insight into our approach to multidimensional tumor profiles and guidance on interpreting their biological impact and diagnostic and therapeutic implications, we present case studies from the NCT/DKFZ molecular tumor board that illustrate our daily practice. This manual is intended to be useful for physicians, biologists, and bioinformaticians involved in the clinical interpretation of genome-wide molecular information.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: NPJ Precis Oncol Año: 2023 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: NPJ Precis Oncol Año: 2023 Tipo del documento: Article País de afiliación: Alemania